A selection of awards recently earned by Dana-Farber and our staff
July – August 2021
The Massachusetts Life Sciences Center recently awarded Dana-Farber a $1.82 million grant titled, Mass Spectrometry Metabolomics Solutions for Highly Scalable Integrated Omics: Charting Metabolic Contributions to Disease Development and Therapeutic Outcomes. The award will help support a new facility at Dana-Farber to provide cutting-edge metabolomics tools for researchers. It will include a unique technology for systematic application of discovery metabolomics for fast, accurate high-resolution mass
profiling of complex biologic samples from patients, and integration with other “omics” data. This data can provide novel insights into metabolic control of cell physiology, disease processes, or response to therapy that can profoundly impact our
basic understanding and clinical treatments. “This critical investment will allow Dana-Farber to expand its use of metabolomics, an exciting technology that can enhance both our understanding of cancer biology as well as therapeutic outcomes,” said
Laurie H. Glimcher, MD, Dana-Farber's president and CEO.
Three senior scientists have received grants from the Dana-Farber's Accelerator Program for research with the potential to be rapidly put to clinical use. The program, administered by the Belfer Office for Dana-Farber Innovations, is designed to close the gap between scientific advances and the translation of those advances into new and better therapies for patients. Funds are awarded for one year to bring research projects to the stage where they can attract investment for clinical development. The 2021 recipients are:
- Pasi Jänne, MD, PhD, director of the Lowe Center for Thoracic Oncology, whose project is The Development of Next-generation Drugs That Target the EGFR Protein in Patients with Non-small Cell Lung Cancer Resistant to the Drug Osimertinib
- Jerome Ritz, MD, director of the Connell and O’Reilly Families Cell Manipulation Core Facility, whose project is The Production and Testing of a Novel CAR T-cell Therapy That Harnesses “Helper” T Cells to Cure Patients with Hard-to-treat B-cell Malignancies
- Eric Smith, MD, PhD, director of Translational Research for Immune Effector Cell Therapies, whose project is Using Genetically Engineered Hematopoietic Stem Cells as Factories for CAR-effector Cells
April – June 2021
U.S. News & World Report has named Dana-Farber/Boston Children’s Cancer and Blood Disorders Center the top pediatric
cancer program in New England and No.2 in the nation in its 2021-22 Best Children’s Hospitals report. Dana-Farber/Boston Children’s has been recognized as one of the top three pediatric cancer centers in the country each year since the ranking’s inception,
earning more No.1 rankings than any other hospital. Boston Children’s Hospital remains the No.1 pediatric hospital in the nation for the eighth consecutive year in U.S. News’ top hospital listings.
Make-A-Wish® Massachusetts and Rhode Island has named Dana-Farber as recipient of the 2021 Community Hero Award. Institute President and CEO Laurie H. Glimcher, MD, accepted
the award on April 10 during the Make-A-Wish Gala: Heroes for Hope, a virtual event. The Community Hero Award recognizes an organization or individual providing vital partnership in the Make-A-Wish Massachusetts and Rhode Island mission to create
life-changing wishes for children with critical illnesses. Dana-Farber has championed the Make-A-Wish mission for more than 30 years, referring more than 2,500 children in Massachusetts and Rhode Island to experience the powerful impact of a wish
A. Thomas Look, MD, of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center,
has received the 2021 Society of Memorial Sloan Kettering Prize. The Society Prize is awarded annually to a researcher, physician, or team leader who has made a positive and lasting impact in the fight against pediatric cancer. Founded in 1946, The
Society of Memorial Sloan Kettering (MSK) is a volunteer-led organization within MSK dedicated to promoting the well-being of patients, supporting cancer research, and providing education on the early prevention, detection, and treatment of cancer.
Alan D’Andrea, MD, director of the Susan F. Smith Center
for Women’s Cancers and the Center for DNA Damage and Repair at Dana-Farber, has been elected
to the prestigious National Academy of Sciences (NAS). The election recognizes D’Andrea’s distinguished and continuing achievements in original scientific research. D’Andrea also serves as the Fuller-American Cancer Society Professor of Radiation
Oncology at Harvard Medical School. Scientists are elected by their peers to the National Academy of Sciences for their outstanding contributions to research. D'Andrea is internationally recognized for his research in DNA damage and repair.
George Demetri, MD, director of the Center for Sarcoma and Bone Oncology at
Dana-Farber, has been elected a Fellow of the American Association for Cancer Research (AACR) Academy. AACR Academy Fellows serve as a global brain trust of top contributors to cancer science and medicine; they help advance the mission of the AACR
to prevent and cure all cancers through research, education, communication, collaboration, science policy and advocacy, and funding for cancer research. Only individuals whose work has had a significant and enduring impact on cancer research are considered
for election and induction into the AACR Academy.
January – March 2021
Dana-Farber, the Broad Institute of MIT and Harvard, and Count Me In, a nonprofit research initiative that conducts patient-partnered studies of cancer, have been awarded a new, $16 million grant from the National Cancer Institute (NCI) to accelerate
research in two rare forms of cancer. The funding will support research projects in leiomyosarcoma and osteosarcoma, two cancers that have seen few recent therapeutic advances. The projects will also yield new information about the best ways to engage
with patients traditionally underrepresented in cancer research.
Benjamin Ebert, MD, PhD, chair of Medical Oncology at Dana-Farber, the George P. Canellos, MD, and the Jean S. Canellos Professor of Medicine at Harvard Medical School, and member of the Broad Institute of Harvard and MIT, has received the Sjöberg Prize, an international accolade given annually for
cancer research. Ebert was honored for his discovery of the mode of action of lenalidomide in the treatment of hematological disorders.
Ebert has also received the prestigious Stanley J. Korsmeyer Award from the American Society for Clinical Investigation (ASCI) for his contributions to the understanding of the genetics, biology, and treatment of myeloid malignancies. The award recognizes
the outstanding achievements of ASCI members in advancing knowledge in a specific field and in mentoring future generations of life science researchers. The award is named in honor of Stanley J. Korsmeyer, MD, a Dana-Farber faculty member, and a dedicated
and accomplished physician-scientist mentor.
Laurie H. Glimcher, MD, Dana-Farber president and CEO, has been recognized by Modern Healthcare as one of 2021’s Women Leaders Luminaries. The honorees are high achievers
who are developing policy, leading change, and guiding health care delivery improvement across the U.S.
The MDS Foundation has honored Ilene Galinsky, BSN, MSN, with its Compassionate Care Award, and Coleman Lindsley, MD, PhD, with its Nobility in Science Award.
Galinsky has been at Dana-Farber for 32 years and is the Senior Adult Leukemia Program research nurse practitioner for the Adult Leukemia Program at Dana-Farber and Brigham and Women’s Hospital.
Lindsley is an assistant professor of Medicine at Dana-Farber and Harvard Medical School. His research focuses on basic and translational investigations of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) – specifically on understanding
the impact of somatic genetic alterations on disease progression and clinical outcomes in patients undergoing allogeneic stem cell transplantation.
Bruce Spiegelman, PhD, recently received the Albert Renold Award, which is a part of the American Diabetes Association’s (ADA) 2021 National Scientific and Health Care Achievement
Awards. This award is presented to an individual whose career is distinguished by outstanding achievements in the training and mentorship of scientists focused on diabetes, and in the development of scientific communities to enhance diabetes research.
Spiegelman’s work focuses on the molecular basis of adipose tissue development and function including systematic metabolism and mitochondrial-dependent energy balance. His work has had translational impact in how obesity and diabetes are treated,
as well as advances in cancer metabolism.
Stuart H. Orkin, MD, of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, is the recipient of the 2021 Gruber Genetics Prize. Orkin is a hematologist-oncologist and
geneticist, and is being recognized for his pioneering discoveries of the genetic underpinnings of blood disorders. His work has not only revolutionized our understanding of how these illnesses occur, but has also led to promising new gene-based therapies
for thalassemia and sickle cell disease, two inherited blood disorders that affect millions of people. Orkin is also the David G. Nathan Distinguished Professor of Pediatrics at Harvard Medical School and an Investigator of the Howard Hughes Medical
Natasha Archer, MD, a physician at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, and an assistant professor of pediatrics at Harvard Medical School, has been
awarded a K08 Clinical Investigator Award by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for her project, “Red blood cell modifiers for plasmodium falciparum growth in sickle cell disease erythrocytes.” The award provides
individuals who have a clinical doctoral degree with an intensive, supervised, research career development experience.
The Wong Family Awards program began in 2012 and the endowment provides a distribution that funds the awards annually: the amount for fiscal 2021 is $300,000. This year’s recipients and their projects are:
- Wallace Bourgeois, MD, who aims to determine if certain novel drugs used in adults might be effective in treating acute myeloid leukemia
(AML) in children. The need is great because only one new drug has been approved in the past 20 years for treating pediatric AML, while there have been eight new drug approvals in the past five years for adults with AML, according to Bourgeois.
- Rizwan Haq, MD, PhD, and Scott Rodig, MD, PhD, who are working to identify immunologic barriers to effective
immunotherapy in uveal melanoma. This extremely rare form of cancer affects the eye, and in more than 50% of patients, the melanoma will spread to other parts of the body with fatal results. Haq and Rodig are using a sophisticated technique called
multiplexed ion beam imaging to identify the type of immune cells present in uveal melanoma tumors: these immune cells could be what prevents existing melanoma therapies from working in the eye.
- Yufei Wang, PhD, who will use her Wong Family award funding to develop chimeric antigen receptor (CAR) T cells capable of mounting an immune
response against solid tumors. CAR T-cell therapy has been used successfully in blood cancers but less so in solid tumors for a variety of reasons. She will equip the CAR T cells with a fine-tuned molecule that will prevent them from being activated
by the smaller number of cancer-related antigens on normal cells, thus avoiding side effects. She is also engineering the CAR T cells with an immune checkpoint inhibitor (ICI) antibody to restore the active anti-tumor immunity and keep the tumor
from turning off the CAR T cells. In her project, Wang will create miniature tumors in the laboratory made from patient samples of metastatic clear cell renal cell carcinoma, to test how well the CAR T cells are working.
Researchers from Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) have received a $14.4 million federal grant for a team-based research project aiming to improve immune-based treatments for glioblastomas, the most lethal brain tumors. The National
Cancer Institute grant will fund the research of 11 investigators in four integrated research projects under the leadership of David Reardon, MD, clinical director of Neuro-Oncology,
and E. Antonio Chiocca, MD, PhD, both of DF/BWCC. The project’s goal is to improve the body’s immune cell recognition and destruction of glioblastoma cells. In addition
to Reardon and Chiocca, team members affiliated with Dana-Farber are: Gordon Freeman, PhD; Donna Neuberg, ScD;
Mario Suva, MD, PhD; Catherine Wu, MD; and Kai Wucherpfennig, MD, PhD.
October – December 2020
Dana-Farber has once again been designated as an LGBTQ Health Care Equality Leader by the Human Rights Campaign Foundation (HRC). This distinction is achieved through evaluation by the Healthcare Equality Index (in which the Institute earned a perfect
score), an annual survey that measures inclusive policies and practices related to LGBTQ+ patients, visitors, and staff. “This distinction tells us we’re on the right path for creating an equitable care experience for everyone,” explains Ildemaro
Gonzalez, vice president, Dana-Farber's chief inclusion and diversity officer. “It’s part of our conscious effort to show patients and employees that when you’re here you can be yourself, and that all are welcomed."
Sarah J. Hill, MD, PhD, has received the National Institutes of Health (NIH) Director’s Early Independence Award for her project titled, “Dissecting the Interaction Between DNA
Damage Repair Defects and the Tumor Microenvironment.” The award “supports exceptional junior scientists who have recently received their doctoral degree or completed their medical residency to skip traditional postdoctoral training and move immediately
into independent research positions.” Hill is a faculty member of both Medical Oncology and Molecular and Cellular
Oncology at Dana-Farber.
Ursula A. Matulonis, MD, has been named this year’s Albany Medical School College Alumni Association’s Distinguished Alumna. Matulonis is chief of Gynecologic Oncology at the Susan F. Smith Center for Women’s Cancers and the Brock-Wilson Family Chair at Dana-Farber.
The Distinguished Alumna award honors an alumnus who has earned national recognition for outstanding leadership in health care.
Loren Walensky, MD, PhD, has recently been named to Nature Bioentrepreneur’s Top 20 Translational Researchers of 2019 list which recognizes researchers who are actively
developing biotechnology to meet a clinical need. Walensky’s clinical interests are hematologic malignancies and his research is directly related to understanding and treating those malignancies. Nature Bioentrepreneur’s Top 20 Translational
Researchers list is based on the researcher’s total number of patents and includes their top-cited patents.
Four Dana-Farber physicians have been named to Expertscape’s Top 15 Breast Cancer Specialists list. They are: Harold Burstein, MD, PhD, institute physician and professor
of medicine; Ian Krop, MD, PhD, associate chief, Breast Oncology; Ann Partridge, MD, MPH, vice chair of
Medical Oncology at Dana-Farber, director of the Adult Survivorship Program,
and founder and director for the Young and Strong Program for Young Women with Breast Cancer;
and Eric P. Winer, MD, senior vice president for Medical Affairs and chief Clinical Development officer, and director of the Dana-Farber/Harvard Cancer Center Breast Cancer's Specialized
Program of Research Excellence. Expertscape is an online platform that identifies and ranks physicians and researchers that excel in the treatment and diagnosis of specific disease conditions.
Lyn Jones, PhD, and Matthew Meyerson, MD, PhD, of Dana-Farber have been named American Association for the Advancement of Science (AAAS) Fellows among the 489 members selected
this year. Meyerson was selected for Biological Sciences and Jones for Pharmaceutical Sciences. Election as a fellow honors members whose efforts advance science, or whose applications in service to society have distinguished them among their peers
Mark Awad, MD, PhD, is recipient of the 2020 ALK-Positive Lung Cancer Research Award. LUNGevity in partnership with ALK-Positive, selected three physicians who focus on high-impact research
related to the treatment of ALK-positive non-small cell lung cancer (NSCLC). The award supports efforts that will transform the disease into a chronic or potentially curable condition instead of a deadly one.
George P. Canellos, MD, will receive this year’s OncLive Giants of Cancer Care award for lymphoma. Canellos, a senior physician with Dana-Farber/Brigham and Women’s Hospital,
is being recognized for his extensive work in the diagnosis and treatment of this cancer. He is one of 15 being honored with the Giants of Cancer Care award in a variety of cancer areas. He has also been the recipient of several other illustrious
awards throughout his career. OncLive’s Giants of Cancer Care award program was developed in 2013 to “celebrate the achievements of leading researchers and educators whose discoveries have helped propel the field forward and established the building
blocks for future advances.” The award recognizes individuals who have achieved landmark successes within the global field of oncology.
Four Dana-Farber physicians have been named to Expertscape’s Top 15 Breast Cancer Specialists list. They are: Harold Burstein, MD, PhD, institute physician and professor
of medicine; Ian Krop, MD, PhD, associate chief, Breast Oncology; Ann Partridge, MD, MPH, vice chair of
Medical Oncology at Dana-Farber, director of the Adult Survivorship Program, and founder and director for the Program for Young Women with Breast Cancer; and Eric P. Winer, MD, senior
vice president for Medical Affairs and chief Clinical Development officer, and director of the Dana-Farber/Harvard Cancer Center Breast Cancer Specialized Program of Research Excellence. Expertscape is an online platform that identifies and ranks
physicians and researchers that excel in the treatment and diagnosis of specific disease conditions.
Lyn Jones, PhD, and Matthew Meyerson, MD, PhD, of Dana-Farber
have been named American Association for the Advancement of Science (AAAS) Fellows among the 489 members selected this year. Meyerson was selected for Biological Sciences and Jones for Pharmaceutical Sciences. Election as a fellow honors members whose
efforts advance science or its applications in service to society have distinguished them among their peers and colleagues. Meyerson is the director of the Center for Cancer Genomics at Dana-Farber as well as a professor of Pathology at Dana-Farber
and Harvard Medical School. Jones is now the director of the Center for Protein Degradation at Dana-Farber.
Donald Alexis, of Dana-Farber Information Services, has been named to the Boston Business Journal’s “40 Under 40” list. This annual award recognizes Boston's “best and brightest young professionals.” Alexis was recognized for his work as president
of Caribbean Integration Community Development (CICD), a housing and community development organization that “creates and maintains affordable housing in areas of Boston where large numbers of people of Caribbean descent reside.”
July – September 2020
Dana-Farber is one of 16 health care organizations across the U.S. receiving the Employer of Excellence award from the American Association of Physician Assistants’ (AAPA) Center for Healthcare Leadership and Management (CHLM). The award showcases organizations
that have implemented practices that create positive work environments for physician assistants (PAs) and encourage collaborative provider teams, stating that “our country needs health care providers working together to meet the demand for high-quality
care. Employer of Excellence winners serve —as outstanding examples of how organizations can establish modern, efficient workplaces that ensure patients get the care they need.”
Lesley Solomon, MBA, Dana-Farber’s senior vice president and chief Innovation officer, is one of 10 health care leaders in Massachusetts honored with the 2020 Extraordinary Women
Advancing Health Care Awards. Each year, the Commonwealth Institute recognizes 10 remarkable leaders shaping health care in Massachusetts. The awards recognize and support recipients for their outstanding career achievements, demonstrating collaboration,
mentorship, innovation, and encouraging diversity.
Laurie H. Glimcher, MD, Dana-Farber’s president and CEO, has been recognized by the Boston Municipal Research Bureau with the 2020 Henry L. Shattuck Public Service Award –
Champion of Business. The award honors individuals who provide dedicated public service to the city of Boston and its community, acknowledging individuals who exemplify “integrity, initiative, leadership, and commitment to the public good.”
Kirsty Hillier, MD, a third-year pediatric hematology/oncology fellow at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center,
is recipient of the American Society of Hematology's (ASH) Research Training Award for Fellows. The award aims to “encourage junior researchers in hematology, hematology/oncology, and other hematology-related training programs to pursue careers in
academic hematology.” Hillier treats patients with hematologic and oncologic disorders at Dana-Farber, and pursues her research interest of the development of lymphocytes and autoreactivity in disorders of the immune system.
The Doris Duke Charitable Foundation has awarded Dana-Farber’s Kenneth Kehl, MD, MPH; David Liu, MD, MPH, MS;
and Srinivas R. Viswanathan, MD, PhD, the 2020 Doris Duke Clinical Scientist Development Award (CSDA). The nationwide program received 208 applicants for
this year’s award, which provides “grants to junior physician-scientists to facilitate their transition to independent clinical research careers.”
William G. Kaelin Jr., MD, has been named the Association of American Cancer Institutes’ Distinguished Scientist for 2020. The AACI is recognizing Kaelin, the Sidney Farber
Professor of Medicine at Harvard Medical School and an investigator at the Howard Hughes Medical Institute, for his long-term research on how cells sense and adapt to changing oxygen levels. The AACI Distinguished Scientist Award was created in 2002
to recognize a major contributor to the field of cancer research.
David Frank, MD, PhD, an associate professor of Medicine at Harvard Medical School, has been named Chair-Elect of the Medical Sciences section of the American Association for the
Advancement of Science (AAAS). Frank’s research lab studies signaling pathways that are important in normal cell growth which become corrupted in cancer. These studies have led to the identification of new targeted therapies currently being tested
in clinical trials. The AAAS is the largest multidisciplinary scientific society in the world, and is the publisher of the journal Science.
George D. Demetri, MD, director of Dana-Farber’s Sarcoma Center, senior vice president for Experimental
Therapeutics, and professor of Medicine at Harvard Medical School, has been honored with the David A. Karnofsky Memorial Award and Lecture by the American Society of Clinical Oncology (ASCO). The award recognizes an oncologist who has made outstanding
contributions to cancer research, diagnosis, and/or treatment. Demetri specializes in sarcomas and studying their biological characteristics in order to help create new therapies to target them. Demetri was instrumental in developing a therapy to
treat gastrointestinal stromal tumor (GIST).
February – June 2020
U.S. News & World Report has named Dana-Farber/Boston Children’s Cancer and Blood Disorders Center the top pediatric
cancer program in New England and No. 2 in the nation in its 2020-21 Best Children’s Hospitals list. Dana-Farber/Boston Children’s has been recognized as one of the top three pediatric cancer centers in the country each year since the ranking’s inception
in 2007, including more No. 1 rankings than any other program. Boston Children’s Hospital remains the No. 1 pediatric hospital in the nation for the seventh year in a row in U.S. News’ top hospital listings.
New England Patriots owner and Institute Trustee Robert K. Kraft has made another gift to honor his longtime partnership with Dana-Farber: the endowed Kraft Family Chair to support the Institute’s innovative work in hematological malignancies. The Chair
will be renamed the Kraft Family and Kenneth C. Anderson, MD, Chair at Dana-Farber, to recognize Anderson’s preeminence in multiple myeloma research.
Heng Li, PhD, assistant professor of Biostatistics and Computational Biology in Data Sciences, will receive funding from the Chan Zuckerberg Initiative (CZI) to support open source software projects
that are essential to biomedical research. CZI’s Essential Open Source Software for Science program announced $5 million in funding for these grants to support software maintenance, growth, development, and community engagement for more than 40 critical
open source tools.
Wendy London, PhD, along with international investigators, recently received a three-year grant from Solving Kids’ Cancer to analyze
biomarkers of survival in high-risk neuroblastoma. Her project is titled, “International Integrated Analysis to Identify Markers of Poor Survival in High-risk Neuroblastoma.” London holds positions as an associate professor of Pediatrics at Harvard
Medical School, director of Biostatistics of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, and faculty director of the Survey and Data Management Core of Dana-Farber Harvard Cancer Center.
Stuart H. Orkin, MD, of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, a David G. Nathan Professor of Pediatrics at Harvard Medical School, and an investigator
at the Howard Hughes Medical Institute, has been named a 2020 King Faisal Prize Laureate in Medicine for his research contributions in hemoglobin disorders.
Harvey Cantor, MD, the Baruj Benacerraf Professor of Immunology at Harvard Medical School, has been named a 2020 Distinguished Fellow of the American Association of Immunologists (AAI).
The program annually recognizes long-term members who have demonstrated excellence in research accomplishment in the field of immunology; exceptional leadership to the immunology community in academia, foundations, nonprofits, industry, or government
at a national or international level; and/or notable distinction as an educator. It is among the highest honors presented by AAI.
Sandy Monteiro, BSN, RN, has been honored with the 2020 Excellence in Nursing Award from the New England Region of the Black Nurses Association. The annual distinction is given to nurses who, in addition to their clinical skills, demonstrate their understanding
of the increasing needs of ethnically, racially, and culturally diverse populations.
Alan D’Andrea, MD, director of the Susan F. Smith Center for Women’s Cancers and director of the Center for DNA Damage and Repair at Dana-Farber, has been honored with
the Lifetime Achievement Award by the Fanconi Anemia Research Fund (FARF). D’Andrea was recognized for dedicating his 30-plus-year career to the advancement of Fanconi anemia (FA) research, and for making tremendous discoveries in understanding DNA
damage in FA and how the FA pathway works. Defects in this pathway account for the chromosome instability and drug sensitivity of many cancers, including women’s cancers, in the general (non-FA) population.
The Pancreatic Cancer Collective, the strategic partnership of the Lustgarten Foundation and Stand Up To Cancer (SU2C), has awarded up to $16 million to four teams of top researchers, including a team at Dana-Farber, as part of its New Therapies Challenge
Grants. The Dana-Farber team will receive up to $4 million over a three-year term for their project led by Alan D. D’Andrea, MD, director of Dana-Farber’s Susan F. Smith Center
for Women’s Cancers and director of the Center for DNA Damage and Repair, and James M. Cleary, MD, PhD. Key collaborators include Geoffrey Shapiro, MD, PhD, director of the Early Drug Development Center and clinical director of the Center for DNA Damage and
Repair; Brian M. Wolpin, MD, MPH, director of the Gastrointestinal Cancer Center and the Hale Family Research Center, and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer;
and Andrew Aguirre, MD, PhD.
Laurie H. Glimcher, MD, Dana-Farber president and CEO, recently was named among “The 100 Most Influential People in Boston.” The list, composed and published by Boston Magazine,
includes politicians, philanthropists, business moguls, and more. Glimcher was recognized for being a renowned immunologist, a “top-notch” fundraiser, and having a collaborative spirit.
Three Dana-Farber faculty members are among the 19 international scientists recently elected to the prestigious Fellows of the American Association for Cancer Research (AACR) Academy. The AACR Academy recognizes and honors distinguished scientists whose
scientific contributions have propelled significant innovation and progress against cancer. The members of the 2020 class of Fellows of the AACR Academy from Dana-Farber are:
Edward J. Benz, Jr. MD, president and CEO Emeritus of Dana-Farber and the Richard and Susan Smith Distinguished Professor at Harvard Medical School, has received the American
Society of Hematology’s (ASH) 2020 Award for Leadership in Promoting Diversity. The award honors hematologists who have supported the development of an inclusive hematology workforce, encouraged the career development of underrepresented minority
trainees, or made a commitment to inclusiveness through contributions in support of ASH’s mission.
November 2019 - January 2020
Dana-Farber Cancer Institute was named one the most noteworthy companies and non-profits led by women in MA. Laurie H. Glimcher, MD, President and CEO is #7 on the 2019 Top
100 Women-Led Business in Massachusetts by the Commonwealth Institute and the Boston Globe Magazine. The list, created by The Commonwealth Institute – a non-profit that supports female business leaders – examined revenue, operating budget,
and other variables, including number of fulltime employees in Massachusetts, workplace and management diversity, and innovative projects.
Dana-Farber was recognized by the Human Rights Campaign as an LGBTQ Health Care Equality Top Performer in
its annual Healthcare Equality Index (HEI). The HEI is recognized as the national benchmarking tool for evaluating the policies and practices of health care facilities as related to the equity and inclusion of their LGBTQ patients, visitors, and employees.
The Worksite Wellness Council of Massachusetts named Dana-Farber a Gold Award winner for the third consecutive year in its annual WorkWell Massachusetts Awards program. The program recognizes the state’s employers of all sizes for their exemplary work
in worksite health promotion and showcases their employee wellness programs’ performance.
Boston Magazine has named more than 110 Dana-Farber-affiliated physicians and surgeons to its annual "Top Doctors" guide. Drawing from a Castle Connolly Medical Ltd. physician database, the list consists of hundreds of Boston-area physicians
from many medical specialties.
Twenty-four Dana-Farber researchers have been named as Highly Cited Researchers, according to the Highly Cited Researchers 2019 list from the Web of Science Group. The following Dana-Farber faculty are on the list: Kenneth C. Anderson, MD; Philippe Armand, MD, PhD; Toni K. Choueiri, MD;
Judy E. Garber, MD, MPH; Anita Giobbie-Hurder, MS; Nathanael S. Gray, PhD; William C. Hahn, MD, PhD; Stephen Hodi, MD; Rafael A. Irizarry, PhD;
Anthony Letai, MD, PhD; Heng Li, PhD; Shirley Liu, PhD; Donna Neuberg, ScD; Patrick A. Ott, MD, PhD; Kornelia Polyak, MD, PhD;
Paul G. Richardson, MD; Jerome Ritz, MD; Chris Sander, PhD; Geoffrey I. Shapiro, MD, PhD; Margaret A. Shipp, MD; Richard M. Stone, MD;
Marc Vidal, PhD; Patrick Y. Wen, MD; Eric P. Winer, MD.
Suneet Agarwal, MD, PhD, co-program leader of the Stem Cell Transplant Center at Dana-Farber/
Boston Children’s Cancer and Blood Disorders Center and an assistant professor at Harvard Medical School, has been awarded the 2019 Excellence in Medicine Award by Team Telomere. Team Telomere is a nonprofit organization dedicated to providing information
and support to those affected by DKC and telomere biology disorders.
The Center for Cancer Genomics (CCG) has awarded grants of $75,000 to Andrew Aguirre, MD, PhD, and Srinivas Viswanathan, MD, PhD,
respectively, for genomics-related research. The awards encourage collaborations among CCG investigators and faculty of Dana-Farber, Brigham and Women’s Hospital, and Boston Children’s Hospital, for projects having broad implications in translational
oncology or precision medicine. Aguirre’s focus will be on using a single-cell RNA sequencing method to predict the effectiveness of drugs within hours from the time of a patient’s biopsy. Viswanathan will use his funding to investigate a rare and
very aggressive disease known as translocation kidney cancer – a form of non-clear cell kidney cancer that makes up only 1-5% of all kidney cancers often affecting young adult patients.
Judith Agudo, PhD, was recently awarded a Career Catalyst Research Grant from Susan G. Komen®. Agudo will use the $450,000 grant to investigate ways to use the immune system
to attack breast cancer cells that have spread to the lungs. The goal is to develop an immunotherapy to target and eliminate breast metastases.
Six Dana-Farber researchers were awarded Career Development Program (CDP) grants from the Leukemia and Lymphoma Society (LLS). The grants support promising early-career researchers who focus on understanding and treating blood cancers and relevant premalignant
conditions. Dana-Farber CDP grant award winners are: Anat Biran, PhD; Juliette Bouyssou, PhD; Sondra Downey-Kopyscinski, PhD; Annamaria Gulla, MD; Shan Lin, PhD; and Gongwei Wu, PhD.
Myles Brown, MD, is the recipient of the 2019 American Association for Cancer Research Distinguished Lectureship in Breast Cancer Research Award, supported by Aflac Inc. He received the
honor at the 2019 San Antonio Breast Cancer Symposium. Brown, the Emil Frei III Professor of Medicine at Dana-Farber and Harvard Medical School, was recognized for his pioneering research involving steroid hormone receptors, which has put a spotlight
on the dynamic ability of these proteins to regulate the genome.
Steven DuBois, MD, director of Experimental Therapeutics at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, senior physician in Pediatric Oncology, and associate professor at Harvard Medical School, has received funding from TeamConnor Childhood Cancer Foundation and the Cookies for Kids’
Cancer organization. The funding will support a clinical trial for ALRN-6924, a drug that blocks certain proteins in tumor cells called MDM2 and MDMX which may be important to the growth of some cancers.
Benjamin L. Ebert, MD, PhD, chair of the Department of Medical Oncology and the George P. Canellos, MD, and Jean S. Canellos Professor of Medicine, recently received
the Meyenburg Stiftung Cancer Research Prize in Germany for his outstanding research on the pathogenesis and treatment of leukemia. Ebert’s laboratory is known for the identification of genetic mutations in blood and bone marrow cells that predispose
older people to developing leukemia and for elucidation of the mechanism of action of thalidomide and its derivatives.
Alexander A. Gimelbrant, PhD, of Chemical Biology, and assistant professor of genetics at Harvard Medical School, is among one of six pairs named to the Pew Charitable
Trusts’ 2019 class of Innovation Fund investigators. His lab focuses on the function of cell identity based on allele-specific gene expression.
Shahrzad Giudici, BSN, RN, received the DAISY Award, a quarterly honor given to an extraordinary member of the nursing department.
Nathanael Gray, PhD, the Nancy-Lurie Marks Professor of Biological Chemistry and Molecular Pharmacology at Dana-Farber Cancer Institute and Harvard Medical School, is one of three
researchers awarded the 2019 Paul Marks Prize for Cancer Research by Memorial Sloan Kettering Cancer Center (MSK). The award recognizes promising scientists for their accomplishments in the area of cancer research. All recipients must be age 45 or
younger at the time of their nomination.
Alejandro Gutierrez, MD, has been recognized with the Milagros para Niños Award for his contributions to improving care for children with cancer, research targeting drug-resistant
cancers, and work in Latin America. He received the award at the Milagros para Niños Gala, where the organization celebrated its 10th anniversary.
Daphne A. Haas-Kogan, MD, and Catherine J. Wu, MD, have been elected to the 2019 National Academy
of Medicine (NAM) for their outstanding professional achievement and commitment to service. It is considered one of the highest honors in the health and medicine fields. Haas-Kogan is a professor of radiation oncology at Harvard Medical School (HMS)
and chair of the Department of Radiation Oncology at Dana-Farber and Brigham and Women’s Hospital.
Wu is a professor of medicine at HMS and chief of Dana-Farber’s Division of Stem Cell Transplantation and Cellular Therapies.
Dana-Farber Cancer Institute’s Heng Li, PhD, Assistant Professor of Biostatistics and Computational Biology in the Department of Data Sciences,
will receive funding from the Chan Zuckerberg Initiative (CZI) to support open source software projects that are essential to biomedical research. CZI’s Essential Open Source Software for Science program, announced $5 million in funding for these
grants to support software maintenance, growth, development, and community engagement for over 40 critical open source tools.
Robert Knoerl, PhD, RN, an instructor in Medicine and nurse scientist in Dana-Farber’s Phyllis F. Cantor Center for Research in Nursing and Patient Care Services,
has been awarded the 2020 Oncology Nursing Society’s (ONS) Victoria Mock New Investigator Award. This award recognizes the contributions of new investigators in building a scientific foundation for oncology nursing practice.
Nikhil Munshi, MD, director of Basic and Correlative Science, and associate director of the Jerome Lipper Multiple Myeloma Center,
has been named president of the International Myeloma Society (IMS). The appointment, announced during the 17th International Myeloma Workshop in Boston, runs for two consecutive two-year terms.
Erin Parry, MD, PhD, of the Department of Medical Oncology, is one of nine physician scientists selected
by the Doris Duke Charitable Foundation to be awarded its Physician Scientist Fellowship in its inaugural year. Parry was recognized for her project entitled, “Dissecting the Mechanisms Underlying Response and Resistance to Immune Checkpoint Blockade
in Richter’s Transformation.”
Kornelia Polyak, MD, PhD, of Dana-Farber Cancer Institute has been named a 2019 Fellow of the American Association for the Advancement of Science (AAAS). Election as an AAAS
Fellow is an honor bestowed upon AAAS members by their peers.
Grant Rowe, MD, PhD, received the David B. Frohnmayer Early Investigator Award from the Fanconi Anemia Research Fund during its Scientific Symposium. Rowe, a physician in Pediatric Hematology/Oncology at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and an instructor of medicine at Harvard Medical School, will use the funding to model the hematopoietic clonal evolution in Fanconi anemia (FA).
Clare Sullivan, BSN, MPH, clinical program manager, Patient Education, was named chair-elect of the Cancer Patient Education Network (CPEN). Renee Siegel, MSW, LCSW, program manager, Patient and Family Advisory Councils, was elected member-at-large. CPEN
is a group of health care professionals who share experiences and best practices in all aspects of cancer patient education.
Myra Tamba, BSN, RN, formerly of Dana-Farber/Brigham and Women’s Cancer Center at Milford Regional Medical Center and now on Dana-Farber’s Longwood campus, received the DAISY Award, a quarterly honor given to an extraordinary member of the nursing department.
Deborah Toffler, MSW, LCSW, received the (Up) Beat Cancer Award at the 12th annual gala, presented by the Joe Andruzzi Foundation (JAF). Each year the award is given to an individual whose work best represents JAF’s mission: providing help, hope, and
a reason to smile for cancer patients and their families by contributing financial support when it is needed most.
With a $4.3 million grant from the federal Cancer Moonshot program, a team of Dana-Farber investigators has launched an effort to understand why immunotherapy drugs, which are dramatically effective in some cases of advanced head and neck cancer, fail
to work in some patients. The multidisciplinary team, led by principal investigator Ravindra Uppaluri, MD, PhD, is using an array of cutting-edge methods to probe immunotherapy
resistance in head and neck tumors – aiming to improve the drugs’ rate of response. Uppaluri, director of surgical oncology in the head and neck program, is working with co-investigators Robert Haddad, MD,
chief of head and neck oncology at Dana-Farber, and David Barbie, MD, associate director, Belfer Center for Applied Cancer Science.
William G. Kaelin Jr., MD, won the 2019 Nobel Prize for Medicine. Kaelin, along with Sir Peter Ratcliffe, FRS, FMedSci, of the University of Oxford, and Gregg Semenza,
MD, PhD, of Johns Hopkins University, was awarded the prize for their discoveries of the molecular system by which cells sense and adapt to varying levels of oxygen availability.
Laurie H. Glimcher, MD, president and CEO of Dana-Farber, received the Distinguished Investigator award from the Massachusetts Society for Medical Research at Massachusetts'
annual Biomedical Research Day meeting and luncheon.
July – September 2019
Dana-Farber has been awarded Magnet® status from the American Nurses Credentialing Center (ANCC) for the fourth consecutive time. This prestigious designation recognizes excellence in nursing practice and health care delivery and has been awarded to only
8% of hospitals in the United States. In 2005, Dana-Farber became the first cancer center in New England to receive Magnet status. There are only five other Massachusetts hospitals who have held Magnet status for this length of time.
The Dana-Farber Inpatient Hospital, located on floors 6B-C-D of Brigham and Women’s Hospital, was recognized with the first team DAISY Award, a quarterly honor given to an extraordinary member of the nursing department.
Dana-Farber has received a $5 million gift from the Edward P. Evans Foundation to create a Center for Myelodysplastic Syndromes (MDS), which will focus on treating, preventing, and ultimately curing the blood disorders.
Dana-Farber/Brigham and Women's Cancer Center has been ranked by U.S. News & World Report as the best for cancer care in New England for the 19th straight year. This year, Dana-Farber/Brigham and Women's Cancer Center is ranked #5 in the nation.
Giada Bianchi, MD, and Zuzana Tothova, MD, PhD, of Medical Oncology, are recipients of the Doris Duke Charitable
Foundation Clinical Scientist Development Award, which provides grants to physician-scientists pursuing independent clinical research careers.
Six Dana-Farber faculty members receive Career Development Program (CDP) grants from The Leukemia & Lymphoma Society (LLS): Anat Biran, PhD; Juliette Bouyssou, PhD; Sondra Downey-Kopyscinski, PhD; Annamaria Gulla, MD; Shan Lin, PhD; and Gongwei Wu, PhD.
Career Development Program (CDP) grants support researchers early in their careers. The funding supports researchers at different stages of their career, from those with less than two years of postdoctoral research to those who hold independent faculty-level
positions. The grants are designed to encourage these promising young investigators to embark on academic careers involving clinical or fundamental research in the blood cancers.
David A. Braun, MD, PhD, the John R. Svenson Fellow in Oncology at Dana-Farber/Brigham and Women’s Hospital, has been recognized by HemOnc Today as a Next Gen Innovator. The honor is presented to early-career hematologists and oncologists who have advanced
their field through innovative approaches in clinical and research settings. Braun’s research focuses on understanding and improving immunotherapies in kidney cancer.
Dipanjan Chowdhury, PhD, chief of the Division of Radiation and Genomic Stability in the Department of Radiation Oncology; Alan D’Andrea, MD,
director of the Susan F. Smith Center for Women’s Cancers and of the Center for DNA Damage and Repair in the Department of Radiation Oncology; and Panos Konstantinopoulos, MD, PhD,
director of translational research, Gynecologic Oncology, and associates at the University of Texas and the University of Pennsylvania have received a four-year, $3.75 million Team Science Grant from the Gray Foundation. The researchers will use the
funding to study the cascade of changes that occur within cells when a key mechanism for repairing damaged DNA breaks down. The grant, announced following a national competition, is one of the first to be awarded by the Gray Foundation’s Basser Initiative,
which fosters research in cancers linked to mutations or malfunctions in the BRCA gene pathways.
Six Dana-Farber researchers have been named to receive Outstanding Investigator awards from the National Cancer Institute (NCI), adding to the Institute’s strong showing in competition for the grants. The R35 Outstanding Investigator Awards, established
in 2014, provide extended grant support to investigators with outstanding records of productivity in cancer research. The newest Dana-Farber recipients are James DeCaprio, MD;
Michael Eck, MD, PhD; Anthony Letai, MD, PhD; David Livingston, MD;
Thomas Roberts, PhD, and David Weinstock, MD. With the addition of these recipients, Dana-Farber
now holds more NCI Outstanding Investigator awards than any other single institution.
Laurie H. Glimcher, MD, president and CEO of Dana-Farber, was named to Modern Healthcare’s list of “50 Most Influential Clinical Executives.” The program recognizes physicians
in the health care industry who are deemed by their peers, and by an expert panel, the most influential in terms of demonstrating leadership and impact.
Philip J. Kranzusch, PhD, assistant professor of Microbiology at Harvard Medical School and Dana-Farber, was named a Pew Scholar in the Biomedical Sciences. Those selected
to join the Pew Scholars Program receive four years of funding to invest in exploratory research to advance human health and address some of the most challenging questions in biomedicine. Kranzusch will investigate how small RNA molecules can activate
an immune response to pathogens for cancer.
Cindy Mackenzie, a locksmith at Dana-Farber and member of the Operating Engineers Union (877), was recently named a Pride Legacy Leader over 50 by Business Equality Network magazine. Mackenzie was initially hired in 1990 as a temporary employee. She’s
now been at the Institute for almost three decades. Business Equality Magazine is committed to reaching and empowering LGBTQ+, women, minority, and other underrepresented, underserved, and underutilized business communities. Its Legacy Leaders over
50 list was created to honor courageous, brilliant, and creative people who have built the foundation of the LGBTQ+ community and its culture.
Matthew G. Oser, MD, PhD, of Medical Oncology, is a recipient of the Damon Runyon Clinical Investigator Award. The award, which is funded by the Damon Runyon Cancer Research Foundation,
supports independent physician-scientists conducting disease-oriented research that demonstrates a high level of innovation and creativity. Oser’s research focuses on developing targeted therapies for small cell lung cancer (SCLC) .
Max Pimkin, MD, PhD, of the Pediatric Stem Cell Transplant program is one of two nationwide recipients of a 2019 Research Grant from the WES (When Everyone Survives) Foundation for
leukemia (and other blood related diseases) research, as well as the recipient of an Emerging Scientist Award from the Children’s Cancer Research Fund, for his proposal entitled: Transcriptional Addiction in Acute Myloid Leukemia (AML).
Rinaa Punglia, MD, MPH, and Daphne Haas-Kogan, MD, Dana-Farber/Brigham and Women’s Cancer Center
radiation oncologists, were awarded ASTRO Fellow (FASTRO) designation by the American Society for Radiation Oncology. ASTRO Fellows program recognizes individuals who have made significant contributions to the field of radiation oncology and to the
Society through research, education, patient care and service to the field. Since its inception in 2006, the FASTRO designation has been awarded to just 353 of ASTRO’s more than 10,000 members worldwide.
Patrick Y. Wen, MD, director of the Center for Neuro-Oncology, received the 2019 Victor Levin Award for Neuro-Oncology Research. Presented by the Society for Neuro-Oncology (SNO),
the award is SNO’s highest honor and recognizes individuals with a career commitment to neuro-oncology, demonstrate leadership, and have made extraordinary achievements in the field.
Jamie White, BSN, RN, of Dana-Farber/Brigham and Women’s Cancer Center at Milford Regional Medical Center, received an individual DAISY award for nursing excellence. The DAISY Foundation (Diseases Attacking the Immune System) established the award in
memory of J. Patrick Barnes, whose parents created the foundation in Patrick’s memory after experiencing firsthand the skills, care, and compassion of nurses.
Edmond M. Chan, MD, is a recipient of the Damon Runyon Physician-Scientist Training Award. The award is given to physicians with novel approaches to fighting cancer, and who show initiative and a commitment to finding new cures.
Paula François, MBA, a financial analyst in Nursing and Patient Care Services, recently graduated from Babson College’s master’s program with a business administration degree (MBA) and a significant accolade. She was awarded the Dr. John D. Attaway Pioneer
Award, named in honor of the first person of color to graduate from Babson with a master’s degree in 1954. The award recognizes recipients for their scholarship, leadership, and service to the Babson community.
Christopher Sweeney, MBBA, presented findings from the ENZAMET trial during the American Society of Clinical Oncology (ASCO) plenary session, where four studies considered
to have the greatest potential influence on patient care are featured, out of more than 6,000 featured abstracts. This was Sweeney’s second time on the plenary stage in five years, making him one of very few presenters in ASCO’s history to have that
Zuzana Tothova, MD, PhD, has been recognized with four recent awards supporting her research in blood cancers:
- She received a Tito Bastianello Young Investigator Award at the MDS 2019 International Symposium in Copenhagen, Denmark. The 10,000-euro award recognized Tothova’s work on mechanisms of cohesin mutations in myelodysplastic syndromes.
- She was elected as one of the 2019 Forbeck Scholars by the William Guy Forbeck Research Foundation. She was recognized in the field of leukemia stem cells, heterogeneity, and metabolism – new directions for AML therapy.
- Tothova received an inaugural RUNX1 Early Career investigator award from the RUNX1 Research Program and Alex’s Lemonade Stand. Her grant will support her research on why secondary mutations in STAG2 help pre-leukemic RUNX1-mutant blood cells in patients
with familial platelet disorder (FPD) progress to leukemia.
- Her fourth award was a discovery research grant from the Edward P. Evans Foundation to support her work on targeting DNA damage repair in cohesin-mutant MDS.
April – June 2019
U.S. News & World Report has named Dana-Farber/Boston Children’s Cancer and Blood Disorders Center the
nation’s No. 1 pediatric cancer program in its Best Children’s Hospitals report. This marks the fifth time since the inception of U.S. News’ pediatric specialty rankings in 2009 that Dana-Farber/Boston Children’s has topped the pediatric
cancer rankings. No other program has ranked No. 1 more than twice.
A $20 million gift from the Saverin Family will establish the Saverin Breast Cancer Research Fund at Dana-Farber under the direction of Eric Winer, MD. The Saverin Family’s commitment is the largest individual gift for breast cancer research in Dana-Farber’s history and the family’s
first major gift to the Institute. The sole purpose of the gift is to support research into treatment and eventual cures of advanced or stage IV metastatic breast cancer.
This summer, Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) will implement a new ambulatory transplant program designed to help some stem cell transplant patients avoid hospital stays. Patients who qualify for the program meet key eligibility
criteria and are scheduled to receive a reduced-intensity allogeneic transplant – also known as a “mini transplant.” This modified form uses lower, less toxic doses of chemotherapy and does not require radiation therapy.
Laurie H. Glimcher, MD, president and CEO of Dana-Farber, was elected to membership of the American Philosophical Society (APS). The APS was founded in 1743 by Benjamin
Franklin for the purpose of “promoting useful knowledge” and is the oldest learned society in the United States. The APS supports research and discovery through grants and fellowships, lectures, publications, prizes, exhibitions, and public education.
Geoffrey R. Oxnard, MD, and Barbara J. Gitlitz, MD, of USC Norris Comprehensive Cancer Center are co-recipients of the Cancer Community (C2) Catalyst Precision Medicine Award.
The honor is presented to individuals that have significantly advanced precision medicine in oncology to bring new, more personalized tests or treatments to patients. Oxnard and Gitlitz, co-principal investigators of the Genomics of Young Lung Study
(GOYL), conducted the first study of lung cancer in adolescents and young adults under the age of 40. They found that about 80 percent of the young lung cancer patients had a driver mutation treatable with available targeted therapies or precision
Avinash Sahu, PhD, is one of three young scientists chosen by the Michelson Medical Research Foundation and the Human Vaccines Project to receive $150,000 each to explore novel approaches toward deciphering how the human immune system fights disease.
Sahu, under the guidance of X. Shirley Liu, PhD, at Dana-Farber and Keith T. Flaherty, MD, at Massachusetts General Hospital, is working in cutting-edge research of artificial
intelligence (AI) and immuno-oncology.
F. Stephen Hodi, MD, and Eric P. Winer, MD, have been inducted into the 2019 class of Giants of Cancer Care®
by OncLive, the official website for the Oncology Specialty Group. They are among 15 oncologists receiving the award, which recognizes individuals selected by their peers for landmark successes within the global field of oncology. Hodi was
chosen in the melanoma and other skin cancers category; Winer was named for achievements in breast cancer.
Harvey Cantor, MD, has received the 2019 Excellence in Mentoring Award from the American Association of Immunologists (AAI) in recognition of his exemplary contributions to future generations
of scientists. Cantor is cited for training students and postdoctoral fellows and for his work as the director of NIH-funded postdoctoral training programs in cancer immunology and HIV-related research.
Gordon Freeman, PhD, and another scientist, Clive Wood, PhD, were pronounced co-inventors on a series of cancer immunotherapy patents previously issued to a Japanese researcher
and Japanese drug company. The U.S. District Court ruled that the patents be corrected to name Freeman and Wood as inventors.
Jennifer Crombie, MD, and Samuel Ng, MD, PhD, were recently awarded pilot grants from the Harold and Virginia
Lash Pilot Grant Fund for Lymphoma Research at Dana-Farber. Established in 2018, Crombie and Ng are the first recipients of these philanthropic funds, given to seed novel studies in lymphoma.
Scott Armstrong, MD, PhD, has been selected to receive the 2019 International Society for Stem Cell Research (ISSCR) Tobias Award Lecture. Established in 2015, the award
is supported by the Tobias Foundation and recognizes original and promising basic hematology research, as well as direct translational or clinical research related to cell therapy in hematological disorders.
Karen Fasciano, PsyD, received the Outstanding Clinical Care Award at the 16th American Psychosocial Oncology Society (APOS) Annual Conference. The award recognizes an exceptional psychosocial oncology clinician for outstanding contributions to the field.
The conference focused on the benefits of team-based interdisciplinary oncology, and how treating the whole patient enhances cancer care.
Cigall Kadoch, PhD, is the recipient of the 2019 Martin and Rose Wachtel Cancer Research Award by the American Association for the Advancement of Science (AAAS) and Science Translational
Medicine. The award, which is funded by an endowment courtesy of Martin Wachtel, honors early-career investigators who have performed outstanding work in the field of cancer research. Kadoch will receive $25,000 and is invited to present her research
at the National Institutes of Health. Her essay will also be published in Science Translational Medicine.
Joseph Mancias, MD, PhD, is one of nine recipients receiving the 2019 Damon Runyon-Rachleff Innovation Award. The Damon Runyon Cancer Research Foundation provides an initial
grant of $400,000 over the course of two years to projects that “have the potential to significantly impact the prevention, diagnosis, and treatment of cancer.”
Matthew Meyerson, MD, PhD, has been named the recipient of the 2019 Alfred G. Knudson Award in Cancer Genetics. Meyerson was honored for his work in advancing the understanding
of the genetic basis of lung cancer. The Alfred G. Knudson award is one of two accolades presented annually by the National Cancer Institute (NCI).
Stuart Orkin, MD, has been elected as a council member for the National Academy of Medicine (NAM). Founded in 1970, the NAM is one of three academies that compose the National Academies
of Sciences, Engineering, and Medicine. As a council member, Orkin will help oversee the policies, procedures, funds, and activities of the Academy. He may also consult on a variety of NAM programs and be asked to serve different council-related committees.
Geoffrey Shapiro, MD, PhD, received the Targeted Anticancer Therapies (TAT) Congress’ Cancer Drug Development Award. TAT is an international organization that is part of
the European Society for Medical Oncology (ESMO). The award acknowledges the dedication and achievements of cancer drug development researchers.
Toni Choueiri, MD, and Colleen Feltmate, MD, recently served on a four-member physician panel at Mohammed
Bin Rashid University (MBRU) of Medicine and Health Sciences in Dubai focusing on career opportunities for medical students. The panel discussion enabled medical students at MBRU to learn about career choices from practicing physicians, get advice
on internships, clinical observerships, and research opportunities, and network with panel members.
James M. Cleary, MD, PhD, and Alan D. D’Andrea, MD, are one of seven research teams participating in
the first round of the Pancreatic Cancer Collective’s “New Therapies Challenge.” An initiative of the Lustgarten Foundation and Stand Up To Cancer, the collective aims to improve pancreatic cancer patient outcomes. They collaborate to advance its
diagnosis and treatment, and to support the field’s next investigators.
January – March 2019
The National Cancer Institute (NCI) has extended funding to Dana-Farber and the Broad Institute of MIT and Harvard to generate new models of cancer that more accurately represent human tumors. Dana-Farber and the Broad will serve as one of only two national
Cancer Model Development Centers (CMDC) for cell line model generation as part of the NCI Human Cancer Models Initiative (HCMI). The new contract provides an additional $3,384,000 to create patient-derived cell line models of cancer for another 18
months, until May 2020, bringing the total funding for this project to $7,351,000.
Boston Magazine has named more than 115 physicians and surgeons affiliated with Dana-Farber to its annual "Top Doctors" guide.
The Chan Zuckerberg Initiative (CZI), in collaboration with the Human Cell Atlas (HCA), has selected Dana-Farber to be a member of their Seed Network. The Institute will join the three-year international effort to create a comprehensive reference map
for all human cells.
Eric Fischer, PhD, of the Department of Cancer Biology;
Cigall Kadoch, PhD, of the Department of Pediatric Oncology;
and Andrew Lane, MD, PhD, of the Department of Medical Oncology are recipients of The Mark Foundation’s inaugural Emerging Leader Awards. The foundation awarded a total of eight grants to promising early-career scientists. The awards fund high-risk, high-reward projects to address unmet needs in cancer risk, prediction,
prevention, detection, and treatment. Founded in 2017 by Alex Knaster, The Mark Foundation for Cancer Research is dedicated to accelerating cures for cancer by using a high-impact approach to funding global groundbreaking research. The goal of the
foundation, named in honor of Knaster’s late father, Mark, who succumbed to cancer, is to reward cutting-edge and innovative scientific ideas that attempt to answer the most complex questions about cancer biology.
Xihao (Sherlock) Hu, PhD, is one of four 2019 Parker Scholars selected by the Parker Institute for Cancer Immunotherapy. The recognition is for early career researchers, graduate students, or researchers entering their first postdoctoral appointment.
The scholars focus on novel projects that answer the most critical research questions in cancer immunotherapy. The Parker Institute for Cancer Immunotherapy was established in 2016 by the Parker Foundation to unite the country’s leading immunologists
at top cancer research institutions nationwide.
Charlotta Lindvall, MD, PhD, of Psychosocial Oncology and Palliative Care has been named a 2018 Sojourns Scholar. The Sojourns Scholar Leadership Program is an initiative led by Cambia Health Foundation that identifies and cultivates the next generation of multidisciplinary palliative care leaders, including nurses, physicians,
psychologists, social workers and pharmacists, among others. Lindvall will receive a grant of $180,000 across two years to fund palliative care research projects, supporting her growth as a national leader in the field.
Kathleen Xie, PhD, a postdoctoral fellow in the laboratory of David Pellman, MD, has received a research fellowship from the Helen Hay Whitney Foundation. The fellowship, which runs
for three years, will support her research into how nuclear atypia – the presence of abnormal nuclei in cancer cells – disrupts gene activity. The Helen Hay Whitney Foundation was established in 1947 and aims to increase the number of imaginative,
well-trained, and dedicated medical scientists. It awards approximately 24 research fellowships annually, for a total of more than 1,100 since its inception.
An international team of investigators led by Wendy Garrett, MD, PhD, and Matthew Meyerson, MD, PhD,
has won a Grand Challenge award from Cancer Research UK to tackle the complex issues of how the intestinal microbiome – the mix of helpful and harmful micro-organisms that reside in the colon – influence colorectal cancer development and treatment.
Other Dana-Farber members of the team are Marios Giannakis, MD, PhD; Kimmie Ng, MD, MPH; and
Shuji Ogino, MD, PhD. The team will receive up to $25 million (20 million British pounds) over five years from the publicly funded research and awareness charity based in the United
Kingdom. The organization’s Grand Challenge awards fund “international, multidisciplinary teams willing to take on the toughest challenges in cancer.”
Michael Constantine, MD, has been named president of the Massachusetts Society of Clinical Oncologists (MSCO). Founded in 1985, the society assists physicians with their
oncology practices including: research grants, educational seminars, and access to an extensive resource library. Prior to assuming this role, Constantine served as MSCO’s treasurer.
Catherine Hulme-Freudenberger, RN, OCN, has been recognized with a DAISY award, a quarterly honor given to an extraordinary
member of the nursing department. Hulme-Freudenberger has been an infusion nurse at Milford for more than 10 years, and a member of the Integrative Nursing team for the past three years. The DAISY Foundation (Diseases Attacking the Immune System)
established the award in memory of J. Patrick Barnes, whose parents create the foundation in Patrick’s memory after experiencing firsthand the skills, care, and compassion of nurses.
Bruce Johnson, MD, chief clinical officer at Dana-Farber and director of the Center for Cancer Precision Medicine, has been named a co-principal investigator for a five-year grant
awarded by the National Cancer Institute (NCI) Human Tumor Atlas Network (HTAN). The NCI HTAN grant – $12.5 million over five years – will be used to create comprehensive atlases of the molecular and cellular geography that exist in different cancers,
identifying altered cells with pre-malignancy state or tumors that are treatment-resistant. This information will help identify patients who are at-risk for becoming resistant to their existing cancer therapies and develop new treatment options for
them resulting in bench to bedside translational care.
Joseph Mancias, MD, PhD, has been named one of nine 2019 recipients of the Damon Runyon-Rachleff Innovation Award. The award funds cancer research by exceptionally creative
thinkers with “high-risk/high-reward” ideas who lack sufficient preliminary data to obtain traditional funding. Only those scientists with a clear vision and passion for cancer research are selected to receive the prestigious award.
Geoffrey Shapiro, MD, PhD, Institute physician, has been given the TAT 2019 Honorary Award for cancer drug development for his leadership in developmental therapeutics, particularly
in solid tumors. The TAT Honorary Award was established to acknowledge distinguished career drug development experts who have devoted a major part of their careers to the discovery and development of better anticancer medicines.
Elizabeth Stover, MD, PhD, medical oncologist in the Division of Gynecologic Oncology, is a 2019 recipient of the Liz Tilberis Early Career Award from the Ovarian Cancer
Research Alliance (OCRA). The award is for junior faculty with a strong commitment to an investigative career in ovarian cancer research. Each grantee will receive a three-year grant of $150,000 per year.
Philippe Armand, MD, PhD, director of clinical research of the Lymphoma Program, and Lakshmi Nayak, MD,
director of the Center for Central Nervous System Lymphoma, have received grants from the Leukemia and Lymphoma Society (LLS). The funding is part of the society’s $42 million commitment to advance new blood cancer treatment approaches including immunotherapy,
genomics, and precision medicine.
Jennifer Crombie, MD, and Samuel Yao-Ming Ng, MD, PhD, were awarded pilot grants in lymphoma.
Benjamin Ebert, MD, PhD, and Matthew Meyerson, MD, PhD, were elected to the National
Academy of Medicine in recognition of their outstanding professional achievement and commitment to service. It is one of the highest honors in the health and medicine fields, and Ebert and Meyerson are two of 85 newly elected members.
Sarah Hill, MD, PhD, Divya Iyer, PhD, and Issac Klein, MD, PhD, are recipients of the Ann and Sol Schreiber Mentored Investigator Award from the Ovarian Cancer Research Alliance (OCRA). The Award provides a total of $75,000 to be used over one or two
years and will encourage the recipient’s research career in the field of ovarian cancer.
Nina Ilic, PhD, Oliver Jonas, PhD, Elizabeth Stover, MD, PhD, and Adam Sperling, MD, PhD, are four Dana-Farber scientists pursuing research funded by the 2019 endowed Wong Family
Awards in Translational Oncology, which support translational oncology and biotechnology development at the Institute. Aiming to make personalize medicine a reality for all patients, the awards recognize “the most meritorious, innovative, translational
projects that utilize information from multiple platforms to develop new diagnostics, prognostic markers, predictive markers, or therapeutics for cancer.” The Wong Family Awards program began in 2012, and the endowment provides a distribution that
funds the awards annually; the amount for 2019 is $300,000.
October – December 2018
Dana-Farber Cancer Institute and Deerfield Management announced an up to $80 million collaboration to create the Center for Protein Degradation at Dana-Farber. The goal of the Center for Protein Degradation is to interrogate and advance a large portfolio
of advanced targeted protein degrader targets while creating a next-generation protein degrader platform. The new Center for Protein Degradation will be led by Nathanael Gray, PhD,
and Eric Fischer, PhD, while operational support, management expertise, and initial funds will be contributed by Deerfield.
The Pan-Mass Challenge (PMC) announced an unprecedented $56 million gift to Dana-Farber Cancer Institute – exceeding last year’s contribution by a staggering $5 million.
Pasi Jänne, MD, PhD, received an Outstanding Investigator Award from the National Cancer Institute (NCI). Up to $600,000 in direct costs per year for seven years is provided to investigators
to work on projects of unusual potential. Award recipients are cancer researchers who have been nominated by their institutions, have served as a principal investigator on an NCI grant for the last five years, and have demonstrated outstanding research.
Justin Kim, PhD, received the 2018 National Institutes of Health (NIH) Director’s New Innovator Award. Established in 2007, the NIH Director’s New Innovator Award supports unusually innovative
research from early career investigators within 10 years of their final degree or clinical residency who have not yet received a research project grant or equivalent NIH grant. Kim, among 58 other highly distinguished innovative scientists, will receive
funding to further his impact on, and address challenges in relation to, biomedical science.
Eric P. Winer, MD, has received the Susan G. Komen Foundation’s 2018 Brinker Award for Clinical Distinction in Clinical Research. Winer was honored for his seminal contributions in improving
breast cancer treatments, which have helped shape the standard of care for breast cancer patients globally.
Susan Bullman, PhD, and Shekinah Elmore, MD, MPH, have been named as 2018 STAT Wunderkinds. STAT Wunderkinds searches for the most impressive young doctors and researchers in the fields of health and medicine in North America.
Pasi A. Jänne, MD, PhD, received the European Society for Medical Oncology (ESMO) Award for Translational Research. ESMO is the leading organization for medical oncology education
and information committed to offering the best treatment to cancer patients. Established in 1985, the award recognizes excellence in medical oncology advancements within the European and international community and was presented to Jänne for his novel
therapeutic agents in patients with lung cancer.
Giovanni Parmigiani, PhD, was awarded the distinction of Fellow by the American Association for the Advancement of Science (AAAS). Parmigiani, among other individuals,
has been elevated to this rank because of his efforts toward advancing science applications that are deemed scientifically or socially distinguished.
David Weinstock, MD, has been named a 2018 Allen Distinguished Investigator by the Allen Institute. The Allen Distinguished Investigator program funds early stage research that
is less likely to receive support from traditional funding sources but has the potential to significantly advance the understanding of biology. Weinstock, who shares the award with Scott Manalis, PhD, of MIT is studying why some lymphoma patients
are cured but others relapse.
David A. Williams, MD, was awarded the 2018 Karl Landsteiner Memorial Award and Lectureship. Initiated in 1954 to honor the late Karl Landsteiner, the distinction is awarded
annually by the American Association of Blood Banks (AABB) to a scientist whose work has profoundly influenced the fields of transfusion medicine and cellular therapies. Williams was recognized for his work on hematopoietic stem cells and how their
interaction with bone marrow can play a role in stem cell engraftment and mobilization.
William G. Kaelin Jr., MD, received the 2018 Massry Prize and will share the $200,000 award with two other scientists, in addition to receiving a 10-ounce gold medal,
for outstanding contributions to the biomedical sciences and the advancement of health. The three researchers were cited for the discovery of the pathway by which cells from humans and most animals sense and adapt to changes in oxygen availability.
May – September 2018
Members of Dana-Farber’s Legislative Action Network (LAN) played a role in the recent passage of a state law raising the age limit for purchasing tobacco products from 18 to 21.
Dana-Farber faculty, patients, family members, and staff have been active in the coalition of the passing of the Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act. As the most comprehensive childhood cancer bill ever taken up by
Congress, expanded research opportunities may improve efforts to track the disease across populations, and improve the quality of life for pediatric cancer survivors.
Dana-Farber/Brigham and Women's Cancer Center was ranked the highest for cancer care in New England for the 18th straight year, by U.S. News & World Report. This year, Dana-Farber/Brigham and Women’s Cancer Center was ranked #4 in the nation.
Dana-Farber was ranked #7 on Forbes 2018's “America’s Best Mid-Size Employers” list.
Dana-Farber/Boston Children's Cancer and Blood Disorders
Center was named the top pediatric cancer program in New England and #3 in the nation by U.S. News & World Report in its new 2018-19 Best Children's Hospitals report.
Matthew S. Davids, MD, of Medical Oncology,
received the first James O. Armitage Lymphoma Clinical Investigator Award at the Pan Pacific Lymphoma Conference. The conference is one of the largest gatherings of experts in lymphoma and transplantation. This award acknowledges a clinical investigator
whose research shows promise and clinical applicability in the area of lymphoma.
Eliezer Van Allen, MD, of Medical Oncology,
has been awarded a Continuation Grant from the Damon Runyon Cancer Research Foundation. The Continuation Grant provides two additional years of support to Damon Runyon Clinical Investigators in need of additional time and funding for their research.
The $300,000 grant is given over a period of two years.
Benjamin Izar, MD, PhD, has received a Career Award for Medical Scientists from the Burroughs Wellcome Fund. The $700,000 award, given over five years, will support Izar’s research
on understanding mechanisms conferring resistance to immune checkpoint inhibitors.
Caron A. Jacobson, MD, MMS, received a 2018 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute (NCI). The award is given to outstanding
mid-career clinical investigators at NCI-Designated Cancer Centers (of which Dana-Farber/Harvard Cancer Center (DF/HCC) is one) in recognition of their extensive involvement in NCI-funded collaborative clinical trials.
Cigall Kadoch, PhD, and Paige Malinowski, manager of Dana-Farber's Young Adult Program,
were recently named among the nation’s top “40 Under 40 in Cancer” by The Lynx Group and McGivney Global Advisors. The inaugural award celebrates the contributions individuals under age 40 make to improve the lives of those affected by cancer.
Nancy Lin, MD, of Medical Oncology and Jean Zhao, PhD, of Dana-Farber's Department of Cancer Biology have received a Breakthrough Award from the U.S. Department of Defense to do preclinical testing of drugs known as CDK4/6 inhibitors for breast cancer that has metastasized to the
brain. The research builds on Zhao and her colleagues discovery that the CDK4/6 protein is often deregulated in HER2-positive breast cancer that has spread to the brain.
Alexandre Detappe, PhD, is one of five young cancer researchers selected to receive a Multiple Myeloma Research Foundation (MMRF) Research Fellow Award. Detappe, a postdoctoral research fellow, is currently focused on “Nanoparticle for Early Detection
of Minimal Residual Disease in Multiple Myeloma.”
Lisa R. Diller, MD, has been named a fellow at the Radcliffe Institute for Advanced Study at Harvard University. Each year, the Radcliffe Institute for Advanced Study supports the
work of 50 fellows in the arts, humanities, sciences, and social sciences. Diller will be the 2018-2019 Lillian Gollay Knafel Fellow at Radcliffe, and will be studying the clinical impact of genetic information associated with increased cancer risk
G. Mike Makrigiorgos, PhD, has received two federal grants totaling nearly $3 million for collaborative research aimed at detecting “needle-in-a-haystack” mutations circulating
in the blood of cancer patients. Both grants from the National Institutes of Health (NIH) support innovative methods to boost the detection of tumor DNA in liquid biopsies.
Stuart H. Orkin, MD, has been selected as the recipient of the 2018 Mechthild Esser Nemmers Prize in Medical Science at Northwestern University. This Nemmers Prize is awarded for
achievement and work of lasting significance in the field of medical science. The prize recognizes major contributions to new knowledge or the development of significant new modes of analysis.
Xiao X. Wei, MD, has received a Young Investigator Award from the Kidney Cancer Association. The one-year grant of $50,000 will help fund urology and clinical oncology research, in line
with the Kidney Cancer Association’s goal of improving the lives of those who have been, and will be, diagnosed with kidney cancer.
Judy E. Garber, MD, MPH, and Bruce Johnson, MD, are among 21 inductees of the 2018 Giants of Cancer Care
recognition program. Respected health care professionals were awarded for advancing the field of oncology for their contributions in research and clinical practice.
Lillian M. Guenther, MD, MPH, David Liu, MD, and Harshabad Singh, MD, were three of only five doctors across the country to receive a 2018 Damon Runyon Cancer Research Foundation Physician-Scientist Training Award. The award supports early career physician-scientists
by incentivizing an academic research career with a significant four-year grant for a mentored research project.
Patrick Ott, MD, PhD, Osama Rahma, MD, Catherine Wu, MD,
and Bradley Pentelute, PhD, of the Massachusetts Institute of Technology, have received a Team Science Award from the Melanoma Research Alliance (MRA). The three-year grant, created with funding from BJ’s Wholesale Club, will support their research
into next-generation neoantigen-targeting peptide vaccines for melanoma patients.
Benjamin Ebert, MD, PhD, has been chosen to join the elite cadre of biomedical scientists chosen by the Howard Hughes Medical Institute (HHMI) to receive long-term, flexible
funding as an HHMI Investigator. Ebert is one of 19 new investigators, chosen from 675 eligible applicants, whose selection was recently announced. Each investigator will receive approximately $8 million over a seven-year term that is renewable pending
a scientific review. The new group of investigators is the first to be appointed to a seven-year term – previously it was five years.
Laurie H. Glimcher, MD, president and CEO of Dana-Farber, has received a Lifetime Achievement Award from the American Association of Immunologists (AAI). The award is presented
in recognition of a remarkable career of scientific achievement and contributions to the AAI and the field of immunology.
Shom Goel, MD, PhD, has been awarded a Komen Career Catalyst Research Grant to investigate strategies for overcoming drug resistance in breast cancer treatment. The $450,000 grant from Susan G. Komen® will be used to research why estrogen receptor positive
(ER-positive) breast cancers become resistant to drugs known as CDK4/6 inhibitors that are initially effective against the tumors.
Irene Ghobrial, MD, co-leader of a Stand Up To Cancer (SU2C) Dream Team, was awarded $10 million for a novel project aimed at detecting individuals with precursor conditions before
they develop full-blown multiple myeloma, an incurable blood cancer.
Jennifer Guerriero, PhD, has been awarded a Komen Career Catalyst Research Grant to study drug resistance in triple-negative breast cancer.
Pasi A. Jänne, MD, PhD, is the 2018 recipient of the Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research from the American Association for
Cancer Research (AACR). The award, named for one of the country’s leading experts in head and neck and lung cancer, recognizes worthy cancer researchers, age 51 and under, who have conducted highly meritorious translational and clinical cancer research.
Christopher J. Recklitis, PhD, MPH, has received a SunSmart: Preventing Secondary Skin Cancer in Young Adult Cancer Survivors Award from the Prevent Cancer
Foundation. Funding from the award will enable him and his colleagues to refine and test SunSmart, a video they produced to prevent skin cancer in young adult survivors of cancer by encouraging proper sun protection.
Michal Sheffer, PhD, has won a Stand Up To Cancer (SU2C) Phillip A. Sharp Innovation in Collaboration Award. Sheffer will work with the University Medical Center Utrecht in the Netherlands and young investigator on the SU2C-Dutch Cancer Society Tumor
Organoids Dream Team. Their project focuses on studies of colorectal cancer patient-derived organoids to validate candidate biomarkers of resistance to natural killer cells.
Several Dana-Farber physicians and researchers received awards or were elected to leadership positions during the annual meeting of the American Association for Cancer Research (AACR):
- Institute President and CEO, Laurie H. Glimcher, MD, was elected a Fellow of the AACR Academy, Class of 2018. The AACR Academy recognizes distinguished scientists whose
major contributions have propelled significant innovation and progress against cancer.
- Judy E. Garber, MD, MPH, was elected to serve on the AACR Nominating Committee for the 2018-2020 term. She was also elected by her colleagues in the AACR Academy to serve
as inaugural AACR Academy President-Elect.
- Utthara Nayar, PhD, a research fellow in the laboratory of Nikhil Wagle, MD, received the prestigious AACR Women in Cancer Research Scholar Award.
Twenty-seven Dana-Farber nurses were recognized in the Boston Globe’s annual “Salute to Nurses” supplement, which ran in conjunction with National Nurses Week. The honorees include:
- Paula Buckley
- Cindy Cao
- Carla Chapman
- Virginia Dalton
- Erin Drury
- Lauren Engel
- Katherine Fleming
- Brittney Fontana
- Karen Francour
- Kristen Graham
- Anne Gray
- Jillian Hoffman
- Kathy Houlahan
- Elizabeth Llewellyn
- Jennifer Lowell
- Jen McKenna
- Elizabeth Newins
- Suzanne Oliver
- Courtney Shea
- Robin Sommers
- Despina Stavros
- Kate Stephans
- Ann Stewart
- Jackie Tuskan
- Meghara Walsh
- Annette Werger
- Alyssa Ywuc
2018 Nursing and Patient Care Services (NPCS) Award recipients include:
- Kathleen Bieglagus, BSN, RN, who was presented with the Thomas M. Kloss Nursing Leadership Award, which recognizes a nurse whose work promotes and fosters the Institute’s mission and core values.
- Janette Danowski Hale, RPh, BCOP, who was presented with the Clinician Collaborator in Care Award, which recognizes a non-NPCS clinician who has demonstrated ongoing, consistent support and appreciation for the contribution of nursing and patient
care services in overall achievement of quality patient outcomes over the past year.
- Amy Ferreira, Damon Morris, and Lindsay Speight, who were presented with the Outstanding Clinic Assistant Award, which recognizes clinic assistants whose practice and teamwork has been exemplary over the past year.
- Nancy Grant, RN, OCN, who was presented with the President’s Award for Nursing Excellence, Dana-Farber’s highest nursing honor, which recognizes a DFCI nurse who demonstrates ongoing dedication and commitment to providing the highest quality oncology
care to patients, families, and the community.
- Nane Kouyoumjian and Scott Maidment, who were presented with the Cancer Care Culture of Care Award for Excellence in Patient Experience, which recognizes NPCS staff members whose work promotes and fosters the Institute’s mission and core values.
- Jeanine McManus, BSN, RN, and Cameron Sze, BSN, RN, who were presented with the Award for Excellence in Relationship-Based Nursing Care, which recognizes exemplary relationship-based nursing care practices.
February – April 2018
Dana-Farber has been recognized for the sixth time as a 2018 leader in LGBTQ Healthcare Equality by the Human Rights
Campaign Foundation. Leaders are determined through evaluation by the Healthcare Equality Index (HEI), an annual survey that measures inclusive policies and practices at more than 2,000 medical facilities nationwide.
Dana-Farber’s blog, Insight, won the first-ever Best in Show honor in the Association of American Medical Colleges Group on Institutional Advancement Awards
for Excellence competition. Insight is a hub of information and inspiration for cancer patients, their friends and families, and the general public.
Dana-Farber’s Office of Workforce Development celebrated its 10-year anniversary, and received two citations for “promoting an inclusive workforce
for advancement in the healthcare industry,” and its “commitment to the development of its current and future workforce through programs that increase access and reduce barriers to personal professional and economic development opportunities.” The
two citations were sponsored by Representative Jeffrey Sanchez and Senator Sonia Chang-Diaz.
Lakshmi Nayak, MD, director of the Central Nervous System Lymphoma Center (CNSLC) and senior
physician at Dana-Farber, and an assistant professor of Neurology at Harvard Medical School, has received the 2018 Leukemia and Lymphoma Society Scholar in Clinical Research Award that supports talented blood cancer researchers in the early phase
of their careers. Nayak will receive grants over a period of five years totaling $625,000.
Rosalind A. Segal, MD, PhD, will receive the 2018 Harold Amos Faculty Diversity Award from Harvard Medical School (HMS). The Harold Amos Faculty Diversity Award was established
to recognize faculty who have made significant achievements in moving HMS and the Harvard School of Dental Medicine forward in becoming a more diverse and inclusive community.
Patrick Y. Wen, MD, director of the Center for Neuro-Oncology and Institute Physician at Dana-Farber and
professor of Neurology at Harvard Medical School, was named board president of the Society for Neuro-Oncology.
Eric Fischer, PhD, a member of Dana-Farber’s Chemical Biology Program,
will receive a 2018 Damon Runyon Cancer Research Foundation Innovation Award that funds research on novel approaches to fighting cancer. Fischer is one of 10 early career scientists selected for the Damon Runyon-Rachleff Innovation Award, and will
receive an initial grant of $300,000 over two years. Each awardee will have the opportunity to receive two additional years of funding at the same level.
Myles Brown, MD, and Judy Garber, MD, MPH, have won a grant to investigate a novel strategy aimed at easing the
transition to menopause for women having their ovaries removed because they carry a mutated cancer risk gene.
Constantine Mitsiades, MD, PhD, has received a Stand Up To Cancer (SU2C) Convergence Team Translational Cancer Research Grant for collaborative studies related
to cancer immunotherapy. SU2C announced a total of $11 million to seven multidisciplinary research teams to investigate immune system response to cancers.
Myles Brown, MD, director of Dana-Farber's Center for Functional Cancer Epigenetics,
is a leader of one of eight international scientific teams receiving Prostate Cancer Foundation Challenge Awards aimed at accelerating new and improved treatments for prostate cancer.
Mary E. Cooley, PhD, RN, FAAN, has been chosen by the Oncology Nursing Society, as its first Scholar-in-Residence to work with leadership in creating a new strategic vision for the society’s research agenda.
Lisa Scherber, director of Patient and Family Programs, was honored at the 79th annual Boston Baseball Writer's Dinner with The Sports Museum Lifetime Achievement Award – given each year to a civic or business leader connected to baseball who positively
impacts the Boston community.
Meghan Underhill-Blazey, PhD, APRN, is the recipient of the Oncology Nursing Society’s Victoria Mock New Investigator Award, which is awarded in recognition of her scientific contributions to oncology nursing. It is one of the society’s highest honors.
Three Dana-Farber physicians from our Susan F. Smith Center for Women’s Cancers have been recognized among the top 27 breast oncologists across the
country by Forbes Magazine: Harold Burstein, MD, PhD, a clinician and clinical investigator in the breast oncology center; Ann Partridge, MD, MPH,
co-founder and director of the young women with breast cancer program and head of adult survivorship; and Eric P. Winer, MD, chief of the division of women’s cancers and senior vice
president for medical affairs, have been selected as exemplary leaders in the field of breast oncology.
Six Dana-Farber scientists are pursuing research funded by the 2018 endowed Wong Family Awards in Translational Oncology, which support translational oncology and biotechnology development at the Institute:
Scott Carter, PhD, and Co-PI R. Coleman Lindsley, MD, PhD, who use cutting-edge methods to extract genotyping data from 17,000 tumor samples generated by the Profile research
Andrew Hong, MD, who is harnessing a technology called MITE to characterize all the possible mutations in a cancer gene known as SMARCB1, which can cause a rare, devastating group of
cancers affecting children and young adults.
Seth Wander, MD, PhD, in collaboration with his research mentor Nikhil Wagle, MD, and the Dana-Farber Center for Cancer Precision Medicine, is investigating the molecular causes of resistance
to CDK 4/6 inhibitors in patients with estrogen receptor-positive metastatic breast cancer.
Pablo Martinez, MD, PhD, and Co-PI Chiara Ambrogio, PhD, are studying a family of proteins known as APOBEC enzymes.
November 2017 – January 2018
Boston magazine has named 79 physicians and surgeons affiliated with Dana-Farber to its annual “Top Doctors” guide. Drawing from a Castle Connolly physician database, the list consists of hundreds of Boston-area physicians from many medical specialties.
Following a two-day site visit, surveyors from the American College of Surgeons Commission on Cancer (CoC) have recommended a full three-year re-accreditation with commendation for Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC). Commendation
was given in five areas: clinical research accrual, oncology nursing care, cancer registrar education, Rapid Quality Reporting System participation, and data submission accuracy.
Tobacco Free Mass, a coalition that has advocated for funding and policies supporting tobacco prevention and cessation for 25 years, recently honored Dana-Farber for its longtime commitment to this mission. The coalition acknowledged Dana-Farber’s “continued
leadership role in the fight against tobacco and its harms.”
Nikhil C. Munshi, MD, received an approximately $11 million grant from the National Institutes of Health (NIH) in support of his research program project, Integrative Oncogenomics
of Multiple Myeloma.
Clare Sullivan, BSN, MPH, OCN, clinical program manager of Patient Education, has been appointed to the board of the Cancer Patient Education Network (CPEN), a national interdisciplinary cancer collaborative founded by the National Cancer Institute (NCI)
to strengthen the role of patient education in cancer care.
Gregory Abel, MD, MPH, and R. Coleman Lindsley, MD, PhD, have received two of the inaugural
research grants from the Dresner Foundation’s Myelodysplastic Syndrome (MDS) Research Fund. The awards support cutting-edge MDS research and related programs to improve future standards of care and ultimately lead to a cure.
Amanda Balboni Iniguez, PhD, a postdoctoral fellow at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, has received the Damon Runyon-Jake Wetchler Award for Pediatric Innovation for her work studying mechanisms of drug resistance in childhood
Paul Nuccio, RRT, FAARC, director of pulmonary services at Brigham and Women’s Hospital and Dana-Farber, received a Lifetime Achievement Award for his years of service to the respiratory therapy profession. Nuccio received the award at the annual meeting
of the Massachusetts Society for Respiratory Care.
Heather Parsons, MD, MPH, has been awarded a three-year postdoctoral fellowship to identify, through changes in circulating tumor DNA, causes of treatment resistance in patients
with HER2-positive metastatic breast cancer. Her research is supported by a grant from Susan G. Komen®.
Ann Partridge, MD, MPH, received the 2017 Edward J. Benz Jr. Award for Advancing the Careers of Women Faculty. The award, previously known as the Advancing the Careers of Women
Faculty Award, was announced by the Office for Faculty Development and Committee for Women Faculty. It was renamed in 2017 to honor the legacy of the former Dana-Farber president and CEO.
Stephen Sallan, MD, received Camp Casco’s first-ever Friend for Life Award during its annual benefit event. The award is given to an outstanding individual whose efforts have deeply
impacted the childhood cancer community. Sallan was recognized for his work in progressing the treatment of acute lymphoblastic leukemia (ALL), the most common form of pediatric cancer.
Andrew Aguirre, MD, PhD, and Andrew Lane, MD, PhD, both of Medical Oncology, are among this year’s recipients
of Clinical Scientist Development Awards from the Doris Duke Charitable Foundation. The awards, which provide $495,000 in research support over three years, are presented to junior scientists who have distinguished themselves by the rigor of their
research and their commitment to future excellence as independent clinical researchers.
Institute scientists were among the recipients of the first Xconomy Awards, honoring people who lead innovation in the Boston life sciences community. David Livingston, MD,
in collaboration with MIT, was the winner of the Xconomy Big Idea Award was the Bridge Project, which fosters collaboration between cancer researchers from MIT and Harvard-affiliated hospitals and schools in addressing challenging problems in cancer
research and care. The recipient of the Xconomy Award in Patient Partnership was Dana-Farber’s Nikhil Wagle, MD, for his work in creating the Metastatic Breast Cancer Project, which
collects and sequences DNA from patients’ tumors and looks for genetic changes that are associated with patients’ response, or lack of response, to treatment.
Dana-Farber Cancer Institute President and CEO, Laurie H. Glimcher, MD, was honored by the AAMC (Association of American Medical Colleges) with the prestigious Award for
Distinguished Research in the Biomedical Sciences at a special presentation during the AAMC annual meeting in Boston. The AAMC cited her numerous discoveries that have advanced treatments for several diseases and chronic conditions, including cancer,
asthma, and osteoporosis.
George Canellos, MD, received a Hope Funds for Cancer Research Award of Excellence in Medicine. The award recognizes outstanding achievements in the fields of basic research,
drug development, medicine, patient support, and philanthropy. Canellos was honored for his work in the development of combination chemotherapy regimens, including one of the first such regimens for breast cancer and one for lymphoma.
William Hahn, MD, PhD, participated in a panel discussion on “The War on Cancer 3.0” as part of the HUBweek Festival. The event provided a forum for Hahn and other prominent cancer
researchers to explore the future of cancer treatment.
Christopher Lathan, MD, MS, MPH, has been recognized as one of 57 local leaders of color in the life sciences and health care sectors. The list was compiled by Get
Konnected, a group launched by Colette Phillips, who runs a communications and marketing firm in Boston.
Patrick Wen, MD, has been elected president of the Society for Neuro-Oncology (SNO). The society is the premier North American organization for clinicians, basic scientists, nurses, and
other health care professionals focusing on central nervous system tumors in children and adults. Mark Kieran, MD, PhD, will become the pediatric representative to the SNO board,
and Ian Dunn, MD, will be the neurosurgical representative. The newly elected members will assume their positions following the SNO annual meeting later this month.